Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > CEO bought 100k - just filed
View:
Post by biorun on Oct 01, 2021 2:55pm

CEO bought 100k - just filed

Ok, shot from the bow. That is a strong signal.
Comment by lscfa on Oct 01, 2021 3:33pm
I hope you're wrong. If an insider is buying there is no material news imminent.   
Comment by biorun on Oct 01, 2021 3:41pm
Not so simple. There is an important nuance to what you are saying. if he has no contract in hand (yet) then the moment he does, then he would be in blackout until it was publicly disclosed. I see this as extreme confidence that he sees something coming, but not yet in actual possession.
Comment by lscfa on Oct 01, 2021 3:43pm
He probably exercised expiring warrants and it has been reported wrong as open market purchase.   
Comment by biorun on Oct 01, 2021 3:47pm
That is also a possibility.
Comment by Ticklel1st on Oct 01, 2021 4:08pm
Biobum..you are nothing but a p.o.S pumper.
Comment by biorun on Oct 01, 2021 4:13pm
Not pumping anything. Everyone controls their own buy and sell button bum tickler. Ultimately if there is something worth taking notice of, then why not point it out. 
Comment by sakinny3 on Oct 02, 2021 3:07am
Comment by Pandora on Oct 01, 2021 4:19pm
As of 11:59pm ET October 1st, 2021 Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction Volume or Value Price Oct 1/21 Oct 1/21 Verrico, Howard Jarman Direct Ownership Common Shares 10 - Acquisition in the public market  ...more  
Comment by forhandlaren on Oct 02, 2021 7:33am
I think the insider buy is more of a strategic nature than a minor addition to the millions of shares that he already owns for growing wealth. According to the last NR there was meetings scheduled with the top-10 pharma company with the sole purpose to nail a deal. So when the CEO bought his 100K the negotiation meetings had begun. Pure speculation, but I think that SBM has put forward pretty ...more  
Comment by biorun on Oct 02, 2021 9:01am
100k in shares will do nothing here to support the share price. Warrant holders would be looking for more of a differential than 2-3 cents on their exercise price. As I said, either we are 5-6 million less in dilution by October 16 or the hammer drops and something goes, along with adding $1M to coffers. Either way, we are better off. The sedi confirms it was a buy on open market, pure and simple ...more  
Comment by lscfa on Oct 04, 2021 3:28pm
Why the hell not acquire more shares by exercising options or warrants even if they are not about to expire? That way money flows to SBM coffers. I still think the insider filing will be corrected to show it was not an open market purchase.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities